# Biomarkers to Detect Endocrine Therapy Resistance

> **NCT06067503** · PHASE2 · RECRUITING · sponsor: **University of Wisconsin, Madison** · enrollment: 8 (estimated)

## Conditions studied

- Metastatic Cancer
- Breast Cancer
- Lobular Breast Carcinoma

## Interventions

- **DRUG:** 18F-fluorofuranylnorprogesterone
- **DEVICE:** Liquid Biopsy
- **DEVICE:** Positron Emission Tomography/Computed Tomography

## Key facts

- **NCT ID:** NCT06067503
- **Lead sponsor:** University of Wisconsin, Madison
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-04-30
- **Primary completion:** 2026-08
- **Final completion:** 2026-08
- **Target enrollment:** 8 (ESTIMATED)
- **Last updated:** 2026-04-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06067503

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06067503, "Biomarkers to Detect Endocrine Therapy Resistance". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06067503. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*